1. Home
  2. ICUCW vs DSGR Comparison

ICUCW vs DSGR Comparison

Compare ICUCW & DSGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICUCW
  • DSGR
  • Stock Information
  • Founded
  • ICUCW N/A
  • DSGR 1952
  • Country
  • ICUCW United States
  • DSGR United States
  • Employees
  • ICUCW 19
  • DSGR N/A
  • Industry
  • ICUCW Biotechnology: Pharmaceutical Preparations
  • DSGR Industrial Machinery/Components
  • Sector
  • ICUCW Health Care
  • DSGR Industrials
  • Exchange
  • ICUCW Nasdaq
  • DSGR Nasdaq
  • Market Cap
  • ICUCW N/A
  • DSGR N/A
  • IPO Year
  • ICUCW 2021
  • DSGR N/A
  • Fundamental
  • Price
  • ICUCW $0.03
  • DSGR $27.60
  • Analyst Decision
  • ICUCW
  • DSGR Buy
  • Analyst Count
  • ICUCW 0
  • DSGR 2
  • Target Price
  • ICUCW N/A
  • DSGR $40.50
  • AVG Volume (30 Days)
  • ICUCW N/A
  • DSGR 71.3K
  • Earning Date
  • ICUCW N/A
  • DSGR 05-01-2025
  • Dividend Yield
  • ICUCW N/A
  • DSGR N/A
  • EPS Growth
  • ICUCW N/A
  • DSGR N/A
  • EPS
  • ICUCW N/A
  • DSGR 0.02
  • Revenue
  • ICUCW N/A
  • DSGR $1,866,047,000.00
  • Revenue This Year
  • ICUCW N/A
  • DSGR $10.80
  • Revenue Next Year
  • ICUCW N/A
  • DSGR $4.10
  • P/E Ratio
  • ICUCW N/A
  • DSGR $1,327.96
  • Revenue Growth
  • ICUCW N/A
  • DSGR 13.91
  • 52 Week Low
  • ICUCW N/A
  • DSGR $21.87
  • 52 Week High
  • ICUCW N/A
  • DSGR $41.47
  • Technical
  • Relative Strength Index (RSI)
  • ICUCW N/A
  • DSGR 56.70
  • Support Level
  • ICUCW N/A
  • DSGR $23.99
  • Resistance Level
  • ICUCW N/A
  • DSGR $27.89
  • Average True Range (ATR)
  • ICUCW 0.00
  • DSGR 1.23
  • MACD
  • ICUCW 0.00
  • DSGR 0.35
  • Stochastic Oscillator
  • ICUCW 0.00
  • DSGR 95.18

About ICUCW SeaStar Medical Holding Corporation Warrant

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

Share on Social Networks: